ΑD	•

Award Number DAMD17-98-1-8354

TITLE: How do Genetic Determinants of Bone Mass Relate to Breast Cancer risk? (97 Breast)

PRINCIPAL INVESTIGATOR: Dorothy A. Nelson, Ph.D.

CONTRACTING ORGANIZATION: Wayne State University
Detroit, Michigan 48202

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)				
	September 1999	Annual (1 A	Aug 98 – 1 Aug	
4. TITLE AND SUBTITLE How Do Genetic Determinants	of Bone Mass Relate to Bre	ast Cancer Risk?	5. FUNDING N	IUMBERS 7-98-1-8354
6. AUTHOR(S) Dorothy A. Nelson, Ph.D.				
7. PERFORMING ORGANIZATION NAI Wayne State University Detroit, Michigan 48202	ME(S) AND ADDRESS(ES)		8. PERFORMIN REPORT NU	G ORGANIZATION MBER
E*Mail: dnelson@intm	ned.wayne.edu			
9.SPONSORING / MONITORING AGEN U.S. Army Medical Research a Fort Detrick, Maryland 21702-	nd Materiel Command	ES)		NG / MONITORING REPORT NUMBER
11. SUPPLEMENTARY NOTES			.1	
12a. DISTRIBUTION / AVAILABILITY S Approved for Public Release				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words	s)			
The purpose of this study is to hormone receptor genes the esti functional mechanism to explain with equal numbers of African-A obtained. We have enrolled 121 American controls), with an age months to an average of 19 subje Preliminary results show that age g/cm² for the radial shaft, 0.351 v different in the two arms (although frequencies. The absent or low-low frequency in the new sample	rogen receptor (ER) and vit this association. We will r mericans and whites. Bon- women (53 white and 20 A range of 40-81. We have i cts per month in the past 3 -, weight-, and ethnicity-ac s 0.348 g/cm ² for distal site that the cell sizes are small), frequency ER genotypes of	tamin D receptor (VDR) ecruit 200 new breast care mineral density (BMI) african-American breast moreased monthly recrumonths, which should a ljusted BMD is higher in the but there is no apparent pserved in our pilot stud	genes. We with ancer cases and by measurement cancer, and 27 itment from 7 pullow accrual of an the cases than the ER genotype difference yet it	Il also explore a possible 200 controls, ages 40-85, as of the forearm will be white and 21 Africanter month in the first 3 400 subjects as planned. It controls (0.805 vs 0.789 frequencies appear to be in the VDR genotype

15. NUMBER OF PAGES 14. SUBJECT TERMS Breast Cancer, Bone Mass, Estrogen Receptor Gene, Vitamin D Receptor Gene, Ethnicity 12 16. PRICE CODE 19. SECURITY CLASSIFICATION 20. LIMITATION OF ABSTRACT 17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION OF THIS PAGE **OF ABSTRACT** Unlimited OF REPORT Unclassified Unclassified Unclassified

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.
Where copyrighted material is quoted, permission has been obtained to use such material.
Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.
Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.
In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).
$\underline{\chi}$ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.
In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.
In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.
In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.
Agroffin alle 8/18/99 PI - Signature Date

TABLE OF CONTENTS

	Page(s)
Front Cover	1
Standard Form (SF) 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body	5-9
Key Research Accomplishments	9-10
Reportable Outcomes	10
Conclusions	10
References	11
Appendix (Figure)	11-12

INTRODUCTION

The **objective** of this study is to investigate the relationship between two polymorphic genes that are potential determinants of bone mass, and breast cancer risk, in African-American and white women, and to explore a possible functional mechanism to explain this association. Our hypothesis is that variations in these receptor genes affect the responsivity of bone and breast tissue to a given level of steroid exposure, and therefore correspond to variations in bone mass and the risk of breast cancer. That is, there may be genetically-determined individual variation in responsivity to identical stimuli that could explain the reported relationship between a higher bone mass and a higher breast cancer risk. Our **specific aims** and **hypotheses** are as follows:

- 1. To compare bone mass and the distribution of genotypes of the VDRG and ERG among 200 new breast cancer cases and 200 controls. Half of each sample will be white ethnicity, the other half African-American. Our **hypothesis** is that: The breast cancer cases will have a higher bone mass and a higher prevalence of the genotypes that are associated with high bone mass; the two ethnic groups will also differ but there are insufficient data to predict in what way they will differ.
- 2. To identify variations within the DNA sequence encoding the structural elements of the ERG; we **hypothesize** that these will correspond with the recognized polymorphic allotypes.
- 3. Our ultimate aim, which follows logically from Aim 2, is to determine the significance of the variations in estrogen receptor (identified in Aim 2) to the stimulation of an estrogen responsive reporter gene regulated by promoters of diverse complexity. Our **hypothesis** is that the variants associated with elevated responsivity of the cell to estrogen will be more prevalent in the breast cancer cases compared with controls

BODY

Progress report for each task relevant to Year 1:

Approved Statement of Work

General: Recruitment and data collection for Specific Aim 1 will take place over the first 2.5 years of the study. New breast cancer patients will be recruited and then matched controls will be recruited in either a concurrent fashion, if practicable, or in a staggered design in which patients are recruited over several weeks and then matched controls are recruited, and the cycle is repeated. This may be necessary because although the bone densitometer is "portable" it is not practical to move it frequently. Analyses of genotypes will be ongoing and will finish 3 months after recruitment ends. Laboratory analyses for Specific Aim 2 will take place in Year 3 after most of the genotype data are available.

<u>Progress:</u> We have been recruiting both new breast cancer patients and controls in a concurrent fashion, although we have concentrated on maximizing the rate of accrual of cases. We have enrolled 73 cases and 48 controls to date. Analyses of genotypes are being done in batches, so that approximately 75% of the subjects in the database also have genotype information available.

Year 1: October 1998-September 1999

TECHNICAL OBJECTIVE 1: To recruit 80 white and 80 black new breast cancer patients and controls (40 each within ethnic groups) and obtain blood samples (for later analysis). Also, to perform bone density measurements and enter the results into the study database.

<u>Progress</u>: As of July 30 1999 we have recruited 53 white and 20 African-American breast cancer patients, and 27 white and 21 African-American controls (total N=121). We began enrollment the last week of September, 1998, so our average rate of accrual is 12 subjects per month. However, our monthly accrual rate has increased from 7 subjects per month in the first three months of the study to 19 per month in the past 3 months (see Figure in Appendix). At the current rate, we expect to enroll 38 more subjects by the end of September 1999, for a total of 159 out of the target sample of 160.

Task 1: Month 1:

Database will be set up. Forms will be copied. Clinic personnel will be contacted to coordinate recruitment of subjects (schedule days and times, work out flow of data collection, etc.)

Progress: Completed

Task 2: Months 2-12:

Study coordinator (full-time research assistant) will attend breast cancer or general medicine clinics at least 3 days per week to recruit 2 subjects per clinic day. Blood sample and bone densitometry will be obtained. Specimens will be transported to Dr. Wooley's lab and stored at -70 degrees. Bone density and questionnaire variables will be entered into database.

<u>Progress:</u> We are proceeding with the protocol as planned, but have had two interruptions. Our first study coordinator stayed only 3 months (through November) and then left for an academic position at a nearby university. We hired a replacement, Linda Darga, Ph.D., in January 1999. The bone densitometer needed repairs in February, and this stopped enrollment for approximately 10 days. The effects of these interruptions on recruitment are reflected in the Figure (see Appendix) for the months of November through February.

The study coordinator, Dr. Darga, is in clinic 4-5 days per week, enrolling an average of 15.7 subjects per month since February. The specimens are transported to Dr. Wooley's lab and/or stored in a freezer the same day they are obtained. The database is updated weekly, and the genotype data are imported into the study database after several batches are analyzed in the lab.

Task 3: Months 3-12: Research assistant will generate interim data reports to be presented at monthly study staff meetings.

<u>Progress</u>: Reports are generated as requested. The study coordinator meets with the P.I. at least once per week, and the study investigators have met as a group twice since the study was initiated. Data summaries of selected variables are presented in the Tables below. No tests of significance are reported at this time because only one-third of our target sample has been accrued, as planned, and they are not deemed to be representative of the final group.

Table 1: Descriptive statistics (mean \pm s.d.) of demographic and bone density data for cases and controls, by ethnic group

	Breast Cancer Cases		Con	trols
Variables	White	African-	White	African-
		American		American
	N=53	N=20	N=27	N=21
Age (yrs)	55.2 ± 10.1	53.3 ± 8.9	48.9 ± 7.4	52.5 ±9.6
Body Mass Index (kg/m²)	27.3 ± 6.3	33.4 ± 9.9	25.8 ± 5.8	31.4 ± 10.7
Age at Menarche	12.5 ± 1.4	12.3 ± 2.0	12.9 ± 1.2	12.7 ± 1.4
(yrs) Age at Menopause	48.1 ± 6.0	44.8 ± 12.1	46.2 ± 6.4	42.9 ± 8.1
(yrs) Distal forearm BMD (g/cm²)	.334 ± .06	$.369 \pm .06$.338 ± .09	.381 ± .08
Proximal forearm BMD (g/cm ²)	.780 ± .10	.830 ± .09	.778 ± .14	.839 ± .07

DISCUSSION: Statistical tests for significant differences between cases and controls are not done at this time because we do not expect the current sample (N=121) to be representative of the final sample (N=400). This is especially true for the controls, where the sample size and age distribution are issues that will be resolved as we focus on recruitment of controls in the next few months that "match" the cases by age and ethnic group, as well as sample size. We will also try to enhance recruitment of African-American women with breast cancer.

The bone density data in Table 1 suggest an ethnic difference (African-Americans greater than whites), as expected (1-2). Since BMD is affected by factors such as age, body size, and the ethnic composition of the samples (3), we also present adjusted means for BMD at the two skeletal sites in Table 2. There is a trend for a higher BMD among the cases, which would support our hypothesis. We plan to adjust bone density by these (and possibly other) covariates as necessary in the full cohort.

TABLE 2: COMPARISON OF UNADJUSTED AND ADJUSTED (AGE, WEIGHT, ETHNICITY) MEANS FOR BONE DENSITY IN THE CASES VERSUS CONTROLS

	Breast Cancer Cases	Controls
Variables	N=68	N=47
Unadjusted Distal Forearm BMD		
(g/cm²)	0.345 ± 0.06	0.357 ± 0.08
Adjusted* Distal Forearm BMD		
(g/cm²)	0.351 ± 0.07	0.348 ± 0.06
Unadjusted Proximal Forearm		
BMD (g/cm ²)	0.794 ± 0.10	0.805 ± 0.12
Adjusted* Proximal Forearm		
BMD (g/cm²)	0.805 ± 0.10	0.789 ± 0.10

^{*}Adjusted for age, weight, and ethnicity

Year 2: October 1999-September 2000

TECHNICAL OBJECTIVE 2: To determine the genotypes for the VDRG and ERG in the breast cancer patients and controls.

Task 4: Months 3-33:

Laboratory assistant under Dr. Wooley's direction will perform genetic analyses. Results will be entered into study database.

<u>Progress:</u> As reported above, genetic analyses are being done in batches and entered at intervals into the database. Summaries of genotypes presently available are provided in the tables below.

Table 3a: Frequencies (actual and percent) of Estrogen Receptor Gene Haplotypes (PvuII and XbaI) in Breast cancer cases (n=61)

	XBAI HAPLOTYPE		
PVUII HAPLOTYPE	XX	Xx	XX
PP	7 (11%)	5 (8%)	1 (2%)
Pp	1 (2%)	21 (34%)	12 (20%)
pp	0	0	14 (23%)

Table 3b: Frequencies (actual and percent) of Estrogen Receptor Gene Haplotypes (PvuII and XbaI) in controls (n=29)

	XBAI HAPLOTYPE		
PVUII HAPLOTYPE	XX	Xx	XX
PP	7 (24%)	1 (3%)	4 (14%)
Pp	0	11 (38%)	2 (7%)
Pp	0	0	4 (14%)

DISCUSSION: The genotype data presented suggest some differences in frequencies of the estrogen receptor gene between cases and controls (Tables 3a and 3b) but no definitive statement can be made using small cell (sample) sizes. The distribution of the cases' genotypes is consistent with those observed in our pilot study (4) preceding the current study. Specifically, the four genotypes in the cases that have either 0 or 1 subject in the cell (XXPp, XXpp, xxPP, Xxpp) are those with the smallest frequencies in the cases from the pilot study. While three of these genotypes are also low-frequency in the controls, the sample size for this group is very small (N=29 out of 200 to be studied).

The VDR genotype frequencies appear to be comparable between cases and controls at this time (Table 4). We intend to continue data collection at the current (if not higher) rate in order to test the original hypotheses stated in the proposal.

TABLE 4: FREQUENCIES (ACTUAL AND PERCENT) OF VITAMIN D RECEPTOR GENE BSM1 HAPLOTYPES IN CASES (N=48) AND CONTROLS (N=27)

	BSM1 HAPLOTYPES			
GROUP	BB Bb bb			
CASES	9 (19%)	19 (40%)	20 (42%)	
CONTROLS	4 (15%)	12 (44%)	11 (41%)	

END OF FIRST YEAR'S TASKS

KEY RESEARCH ACCOMPLISHMENTS

- Recruitment of 12 subjects per month, on average, for a total of 121. An increase in the accrual rate to 19 per month since May 1999 should yield a year-end total of 159 of the targeted 160 research subjects.
- Recruitment of both African-American and white cases and controls.
- Recruitment of subjects over most of the targeted age range (40-81 compared with the target of 40-85).

- A database that is clean and up to date.
- The genotyping of specimens at a reasonable rate (75% of enrolled subjects at any time).
- The expectation of meeting our goal of recruiting 400 subjects by the middle of the third year of the study.

REPORTABLE OUTCOMES

- Development of serum repository for genotyping.
- Database development for all study variables.

CONCLUSIONS

We conclude that the proposed protocol for recruitment and study of 400 subjects over 3 years is realistic and productive. The preliminary data in 121 of the subjects suggest that there is a trend for bone density in the proximal and distal forearm, when adjusted for age, weight, and ethnicity, to be higher in the cases as predicted. There are apparent differences between cases and controls in the genotype frequencies for the Estrogen Receptor Gene that are consistent with the findings of our previous pilot study (4). No definitive conclusions can be drawn at this time, but the preliminary results indicate that continued recruitment and study of our target sample will provide appropriate data for the evaluation of our hypotheses. The knowledge to be gained from this study may provide new tools for assessing breast cancer risk early in life (such as bone mass measurement or genotyping) that could lead to modifications in hormone replacement therapy in postmenopausal women and/or increased surveillance for breast cancer in women with high bone mass.


Our plans for the immediate future include an emphasis on recruiting age-appropriate controls in order to match the current sample for cases. Thereafter, we will try to stagger recruitment in both groups to keep them comparable for interim analyses. We need to enhance recruitment of African-Americans in the breast cancer arm, although to the best of our knowledge there has been no significant recruitment bias by ethnicity. We believe that our sample of breast cancer cases is representative of the ethnic composition of the clinic population. We are making efforts to reach other potential subjects through community cancer outreach centers, where volunteers are being trained to identify possible recruits and provide the necessary information and help to determine their interest in the study and ensure that we contact them.

REFERENCES:

- 1. Kleerekoper M, Nelson DA, Peterson EL, Flynn MJ, Pawluszka AS, Jacobsen G, Wilson P. Reference data for bone mass, calciotropic hormones and biochemical markers of bone remodeling in older (55-75), postmenopausal white and black women. *J Bone Miner Res* 9:1267-1276 (1994).
- 2. Nelson DA, Villa ML. Racial/ethnic influences on osteoporosis risk. In: Rosen C, Glowacki J, Bilezikian J, eds. *The Aging Skeleton*. San Diego: Academic Press (1999).
- 3. Nelson DA, Feingold M, Bolin F, Parfitt AM. Principal components analysis of regional bone density in black and white women: relationship to body size and composition. *Amer J Phys Anthropol* **86**:507-514 (1991).
- 4. Nelson DA, Kleerekoper M, Brooks SC, Du W, Wooley, PH. Distribution of estrogen receptor genotypes in breast cancer compared with control subjects: possible relationship to bone density. *Bone* 23(Suppl):S270 (1998).

APPENDIX: FIGURE: Monthly recruitment rate from September 1998 through July 1999.

subjects per month



Months (Sept. 1998-July 1999)

MONTHLY PATIENT ACCRUAL RATE

12